Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxyphenbutazone Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.94 |
| ▸ | LMNA | P02545 | 3/20 | 0.94 |
| ▸ | RAB9A | P51151 | 3/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.94 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.94 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.94 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.94 |
| ▸ | TP53 | P04637 | 1/20 | 0.94 |
| ▸ | MAPT | P10636 | 1/20 | 0.94 |
| ▸ | HPGD | P15428 | 1/20 | 0.94 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.94 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxyphenbutazone Anhydrous SCHEMBL25854 | 0.99 | LMNA (0.97) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL3182776 | 0.99 | LMNA (0.97) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL2525061 | 0.99 | LMNA (0.97) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL1263248 | 0.99 | LMNA (0.97) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL25856 | 0.97 | LMNA (1.00) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL25857 | 0.97 | LMNA (1.00) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL5316370 | 0.97 | LMNA (1.00) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL11337449 | 0.97 | LMNA (1.00) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL28278628 | 0.94 | LMNA (0.94) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL5612853 | 0.93 | LMNA (0.92) | LMNARAB9AALDH1A1CYP3A4PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117426772-A | Dual function acrylate hydrogel film for diffusion limiting films and attenuating foreign body reactions | 美敦力迷你迈德公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117098517-A | Drug eluting stent | 赛诺医疗科学技术股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-108135875-B | Methods and compositions for treating metabolic reprogramming disorders | 约翰霍普金斯大学 | 2021-12-31 | — | — | CN | disclosed |
| CN-113384701-A | Compositions and methods for treating neuropsychiatric disorders using endothelin-B receptor agonists | 美国中西部大学 | 2021-09-14 | — | — | CN | disclosed |
| CN-108290827-B | Prodrugs of glutamine analogs | 约翰霍普金斯大学 | 2021-01-01 | — | — | CN | disclosed |
| US-20110027188-A1 | Methods, Compositions and Devices for Treating Lesioned Sites Using Bioabsorbable Carriers | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2011-02-03 | — | — | US | disclosed |